Skip to main content
. 2017 Nov 23;8:1432. doi: 10.3389/fimmu.2017.01432

Figure 5.

Figure 5

The peptibodies BKT130Fc and BKT120Fc inhibit the in vitro migration of different chemokines. A transmigration assay was performed to study the effects of the BKT130Fc, BKT120Fc and BKT110Fc peptibodies on in vitro migration. (A) Migration toward CCL2 was assessed using THP-1 cells. (B) Migration toward CCL5 was assessed using THP-1 cells. (C) Migration toward CXCL10 was assessed using Jurkat cells overexpressing CXCR3. (D) Migration toward CXCL11 was assessed using Jurkat cells overexpressing CXCR3. (E) Migration toward CXCL12 was assessed using CD4+ T cells. BKT130Fc, BKT120Fc, and BKT110Fc were added at 10 µg/ml. The results, analyzed using Student’s t-tests (*p ≤ 0.05), are expressed as the mean percentage of migration ±SD. (F) Dosing of BKT130Fc pharmacokinetics (PK). C57BL/6 mice (n = 3) were intravenously (i.v.) injected with 25, 50, or 100 μg of BKT130Fc. The serum peptibody levels were tested after 2 h, 24 h, and 6 days. (G) PK of BKT130Fc and BKT120c in mice. C57BL/6 mice (n = 5) were i.v. injected with BKT120Fc or BKT130Fc at 50 µg/mouse. The serum peptibody levels were tested after 2 h, 24 h, and 6, 11, and 18 days. (H) BKT130Fc and BKT120Fc inhibited delayed-type hypersensitivity (DTH) in vivo. DTH model was established in female BALB/c mice (n = 12). BKT120Fc, BKT130Fc, or BKT110Fc were intravenously injected (50 μg/mouse) on day 0 and 24 h before the challenge (day 5) (total of 100 μg/mouse). Dexamethasone (100 µg/muse) served as the positive control. The two dotted lines indicate the normal range of ear swelling. The results, analyzed using Student’s t-tests (*p ≤ 0.05), are expressed as the mean ± SE of ear swelling (mm). All the DTH experiments were performed at least four times.